Interferons are currently assigned to three classes on the basis of the cells that produce them (reviewed in ref. 1); a and X interferons (IFN-a and IFN-f) are produced by leukocytes and fibroblasts, respectively, in response to viral infection, whereas y interferon (IFN-y) is produced by T-lymphocytes when stimulated by mitogens or by antigens to which they had previously been sensitized. Each of these interferons was originally identified through its inhibition of viral growth. In addition to their well-documented antiviral activities, crude interferons also occasionally have been observed to suppress the growth of other nonviral intracellular infectious agents (reviewed in ref. 2) . In studying the antiviral-like action of interferon against Toxoplasma gondii, an obligate intracellular protozoan parasite, it is important that macrophages not be used as the host cells. Activated macrophages are known to kill intracellular T. gondii (3) , and macrophageactivating factor might be present in crude interferon preparations. Indeed, macrophage-activating factor and IFN-y may well be the same substance. Several laboratories have reported that interferon blocked the growth of T. gondii in cultured fibroblast or epithelial cells (4) (5) (6) . Shirahata and Shimizu (6) have presented evidence that IFN-y is the active substance in their studies of the inhibition of T. gondii. Experiments done in this laboratory showed that human recombinant IFN-a and IFN-,B had no effect on T. gondii. However, treatment of human fibroblasts with 8 to 16 units of human recombinant IFN-y per ml blocked the growth of T. gondii. This IFN-y inhibited vesicular stomatitis virus at 4 units/ml with the same line of human fibroblast as host cells (unpublished data) .
The biochemical basis of the antiviral state induced by the various interferons is now reasonably well understood (reviewed in ref. 7) . In reviewing the action of interferon on nonviral agents, Vildek and Jahiel (2) suggested 13 yr ago that inhibitory mechanisms different from those that block viral growth were likely to be involved. This report presents evidence for an antitoxoplasma mechanism induced by IFNy that is totally different from the well-studied antiviral state induced by interferons.
MATERIALS AND METHODS
Host Cells and Parasites. Human fibroblasts were grown in Eagle's (8) minimal essential medium supplemented with antibiotics and 10% fetal bovine serum. The serum concentration was reduced to 3% for infection or for treatment with interferon. Medium without tryptophan was prepared from a kit supplied by GIBCO and supplemented with dialyzed fetal bovine serum. Cloned T. gondii of the RH strain were maintained by serial passage in human fibroblast cultures and assayed by plaque formation, with the results reported as plaque-forming units as described (9) .
Interferons and Their Titration. Human recombinant IFNa, IFN-p, and IFN-y were supplied by Genentech (San Francisco, CA) (10). They were stored at 4°C at 106 units/ml in 0.5 M NaCl/20 mM Tris, pH 8/1% 2-mercaptoethanol. All interferon concentrations reported here are based on assays done at Genentech with HeLa cells and vesicular stomatitis virus. Titrations done in this laboratory with human fibroblasts and vesicular stomatitis virus found these interferons slightly less potent. The lowest concentrations that suppressed the growth of vesicular stomatitis virus in human fibroblasts were 2, 2, and 4 units/ml for the IFN-a, IFN-P, and IFN-y, respectively. Plaque reduction assays (unpublished data) of the activity of IFN-y against T. gondii were carried out in parallel with every experiment reported here and always showed complete inhibition of plaque formation at 8 to 16 units/ml. The extent of the inhibition of the growth of T. gondii was measured 1 and 2 days after infection by the incorporation of [3H] uracil. This precursor is incorporated by T. gondii but not by the host cell because only the parasite contains significant quantities of uracil phosphoribosyltransferase (EC 2.4.2.9) (11). Infected human fibroblast monolayer cultures in trays that contain 24 wells 1.6 cm in diameter were labeled by the addition of 5 ,uCi (1 Ci = 37 GBq) of [3H]uracil without changing the medium. Two hours later the acid-precipitable radioactivity was measured. Because T. gondii has a generation time of 7-8 hr, incorpo-
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The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. ration of [3H]uracil during a brief pulse 1 or 2 days after infection is a valid measure of parasite growth. In parallel experiments, the antiparasitic activity of IFN-y measured by this radiometric assay of T. gondii growth was identical to the activity obtained by measuring the inhibition of parasite growth in a plaque assay (unpublished data).
Acid-Soluble Pools. The uptake of [3H]tryptophan into the acid-soluble pool of human fibroblasts was measured by using confluent cultures grown on round glass coverslips 1.2 cm in diameter. These coverslips were dipped into Hanks' (12) balanced salt solution to wash away the existing medium and then incubated at 370C for 6 sec or longer in fresh medium that contained [3H]tryptophan (75 u.Ci/ml). The exposure to this radioactive medium was ended by four successive dips in ice-cold phosphate-buffered saline. The acid-soluble pool was then extracted with cold 0.3 M trichloroacetic acid for 1 hr. The acid extract was centrifuged at 12,000 x g for 30 sec, and the radioactivity of the supernatant fluid was measured.
Chromatography and Electrophoresis. Tryptophan (Rf = 0.65) was separated from a mixture of N-formylkynurenine and kynurenine (Rf = 0.85) by ascending chromatography on Whatman 3MM paper in 0.1 M HCl. All three substances were resolved by a two-dimensional separation that used thin-layer cellulose ascending chromatography at pH 1.85 in a solution that contained 0.67 M acetic acid and 0.5 M formic acid, followed by electrophoresis (50 V/cm) in the same solution without drying the thin layer. Spots were located by fluorescence under long UV illumination, by the ninhydrin reaction, or by autoradiography using Kodak XPR-1 x-ray film.
Charcoal Adsorption. The aromatic compounds in the medium of cultures treated with interferon were concentrated and desalted by adsorption onto and elution from charcoal. Medium that had been prepared without phenol red was shaken with charcoal (1 mg/ml) for 30 min. 
RESULTS
The minimal concentration of IFN-y that blocked the growth of T. gondii as measured by the specific incorporation of
[3H]uracil was consistently 2-fold higher in Dulbecco's (13) modified minimal essential medium than it was in Eagle's (8) original minimal essential medium. Individual tests of each of the 27 quantitative and qualitative differences between these two media showed that the critical ingredient was tryptophan, which is supplied at 10 ,ug/ml in Eagle's medium and 16 ,ug/ml in Dulbecco's medium. A systematic analysis of the dependence of the IFN-y activity upon the tryptophan concentration in the medium is shown in Fig. 1 . The data from infected cultures that were not treated with IFN-y showed that the growth of T. gondii was independent of the tryptophan concentration in the medium. One day after infection, the same incorporation of [3H] uracil was observed in cultures with tryptophan concentrations that ranged from 0 to 30 ,g/ml. Normal short-term growth of T. gondii within cells incubated in medium lacking tryptophan does not prove that the parasite can synthesize this amino acid. T. gondii may well have grown at the expense of tryptophan in the acid-soluble pool of the host cell, which would be replen- ished by protein turnover in the absence of this essential amino acid in the medium. Fig. 1 shows that the concentration of tryptophan in the medium markedly affected the antitoxoplasma activity of IFN-y at 16 units/ml, which was the minimal inhibitory concentration in the titration carried out in Eagle's medium. Doubling the 10 ,ug of tryptophan found per ml of this medium completely blocked the effect of the IFN-y. This observation was confirmed and extended by titrating the antitoxoplasma activity of IFN-y in media prepared with four different tryptophan concentrations. Fig. 2 The growth of T. gondii in these cultures was not affected by the tryptophan content of the media (see Fig. 1 ). The concentrations of tryptophan in the media were 0,ug/ml (A), 2 ,Ag/ml (A), 10 A.g/ml (o), and 50 ,Ag/ml (o).
titrations yielded four roughly parallel curves with progressively more IFN-y required to inhibit the parasite as the tryptophan concentration in the medium was increased.
The observed interdependence of the tryptophan concentration in the medium and the antitoxoplasma activity induced by IFN-y in human fibroblasts suggested two models. In the first, interferon induces the host cell to degrade tryptophan. In the second model, interferon induces a defect in tryptophan transport by host-cell plasma membrane. If T. gondii, like its host cell, requires tryptophan for growth, markedly reduced transport of this amino acid by the plasma membrane of the host cell could result in starvation of the parasite. Such starvation might even preferentially affect the parasite because it grows within a cytoplasmic vacuole-the parasitophorous vacuole-that is thought to be derived, at least in part, from the plasma membrane of the host cell (14) . If the vacuolar membrane shared the postulated permeability defect of the plasma membrane, tryptophan in the medium would have to pass this barrier twice before it could be available to the parasite.
The model of impaired tryptophan transport induced by IFN-y was tested by comparing the uptake of radioactive tryptophan into the acid-soluble pools of control and treated cultures. The acid-soluble pool of the control cultures was Fig. 3 .
The tryptophan metabolites that accumulate within cells that were treated with IFN-y do ultimately leak into the medium. When confluent human fibroblasts cultures were treated for 3 days with 64 units of IFN-y per ml of medium that contained [14C]tryptophan, the cpm/ml of the medium remained approximately the same as measured in daily samples. However, the percentage of the radioactivity that cochromatographed with authentic tryptophan decreased progressively from >95% in control cultures to <20% in cultures treated with IFN-y for 2 days (Fig. 4) . In this latter sample, most of the radioactivity in the medium migrated more rapidly than did tryptophan when analyzed by ascending paper chromatography in 0. 10 ,uCi/ml. The medium from these cultures was harvested after 1 and 2 days of incubation, while control medium was harvested from a third culture after 2 days of incubation. Most of the tryptophan from the medium of the culture treated for 2 days with IFN-y at 64 units/ml was converted to other radioactive metabolites (Fig. 4) Proc. Natl. Acad. Sd USA 81 (1984) ,0 0 Examination of various fluorescent degradation products of tryptophan showed that most of the radioactivity was associated with two substances, kynurenine and N-formylkynurenine. Part of the evidence for this identification is shown in Fig. 5 , which presents autoradiographs of a two-dimensional thin-layer chromatographic/electrophoretic procedure that completely resolved tryptophan, kynurenine, and N-formylkynurenine, These three known compounds were added to the medium samples just before analysis and were subsequently located by the ninhydrin reaction. All of the radioactivity in the medium of cultures incubated for 2 days without interferon migrated with tryptophan (Fig. SA) . However, after 1 day of incubation with cells treated with IFN-y, some of the radioactivity supplied as tryptophan migrated with kynurenine and N-formylkynurenine (Fig. 5B) . Most of the radioactivity from the medium of cultures treated with IFN-y for 2 days, migrated with kynurenine, with lesser amounts associated with N-formylkynurenine and tryptophan. Both media contained 10 ,uCi of [14C]tryptophan per ml. Samples of the medium were diluted 2-fold with an aqueous solution of tryptophan and kynurenine at 5 mg/ml each and N-formylkynurenine at 10 mg/ml. This mixture was analyzed by two-dimensional thin-layer chromatography and electrophoresis in a mixture offormic and acetic acids. The radioactive spots on the thin layer were located by autoradiography with an 8-day exposure. These autoradiograms contain all of the radioactive spots that were detected. The ninhydrin spots of tryptophan (Trp), kynurenine (K) , and N-formylkynurenine (FK) are drawn on the developed x-ray film. (A) Control culture after incubation for 1 day. (B and C). IFN-y-treated cultures after incubation for 1 day (B) and for 2 days (C).
ed by autoradiography, in each of 10 different chromatographic solvents. This identification was further confirmed by fluorescence spectroscopy with unlabeled material that had been isolated from the medium of interferon-treated cultures by adsorption onto and elution from charcoal and then purified by two-dimensional chromatography/electrophoresis. The principal tryptophan metabolite and authentic kynurenine had similar fluorescence emission spectra with the same maxima.
Once the principal tryptophan metabolites found in the medium were identified, it was possible to re-examine the nature of the high level of radioactivity found in the acidsoluble pool of human fibroblasts that had been treated with IFN-y (Fig. 4) . Two-dimensional chromatographic/electrophoretic analyses of the acid-soluble pool extracted 5 min after exposure to medium that contained [3H]tryptophan showed that <1% of the intracellular radioactivity was in the form of tryptophan, while kynurenine and N-formylkynurenine accounted for 30% and 70% respectively. DISCUSSION Treatment with IFN-y induced human fibroblasts to degrade tryptophan. Although the enzymes involved in this degradation have not yet been measured, their identity seems clear on the basis of the principal tryptophan metabolites isolated from the medium. The main degradation product of radioactive tryptophan was proven to be kynurenine by cochromatography and coelectrophoresis with the authentic substance under a wide variety of conditions. This identification was confirmed by a comparison of fluorescence emission spectra. The second most prominent degradation product, N-formylkynurenine was identified only electrophoretically and chromatographically. However, the fact that N-formylkynurenine is known to be the biochemical intermediate between tryptophan and kynurenine (Fig. 6 ) serves to confirm its identification. Thus IFN-y must, at a minimum, induce an increase in the activity of the enzyme tryptophan 2,3-dioxygenase (EC 1.13.11.11) that converts tryptophan to N-formylkynurenine. It remains to be determined if the activity of the second enzyme in the tryptophan degradation pathway, formamidase (aryl-formylamine amidohydrolase, EC 3.5.1.9) is also increased. It is certainly possible that both of these enzymes are induced because IFN-y has been reported to elicit the synthesis of at least three new mRNAs (16) ed (2'-5')A polymerase), and a protein kinase. Each of these enzymes, when activated by double-stranded RNA made during viral infection, serves to compromise protein synthesis. The (2'-5')A polymerase makes (2'-5')oligo(A), a series of short oligonucleotides in which the adenylic acid residues are linked by a (2'-5')phosphodiester bond. A (2'-5')A polymerase (18, 19) and a kinase (20) that phosphorylates initiation factor eIF-2 are also induced by IFN-y, but their roles in the antiviral action of this interferon have not been conclusively defined.
The possible antitoxoplasma role of the host cell (2'-5')A polymerase and protein kinase induced by IFN-y must be considered with reference to the intracellular site of T. gondii. This parasite grows within a membrane-bound structure, the parasitophorous vacuole, that lies within the cytoplasm of its host cell (14 (Fig. 2) . In constructing these hypotheses, the assumption was made that T. gondii, like its host cell, was incapable of tryptophan synthesis.
The intracellular degradation of tryptophan by the host cell in response to treatment with IFN-y could restrict the growth of T. gondii in at least two ways. One or more of the tryptophan metabolites could be toxic to the parasite in a manner that was reversible by tryptophan. Alternatively, the degradation of tryptophan could so reduce its concentration in the acid-soluble pool of the host cell that the intracellular parasites would be starved for an essential amino acid. The first of these hypotheses is readily testable by examining the effect of ultrafiltrates of medium from IFN-ytreated cultures. The low amounts of tryptophan in the acid-soluble pool of cultures treated with IFN--y provide suggestive evidence for the second hypothesis.
Both crude and purified natural human IFN-y also induce fibroblasts to degrade tryptophan (unpublished data). However, it remains to be determined if the antitoxoplasma state produced in vitro by the degradation of tryptophan has any significance in vivo, where the concentration of tryptophan in blood is about 7 ug/ml (21) . It should be noted that there is no evidence that infection with T. gondii was needed to trigger the IFN-y-treated cells to degrade tryptophan. The experiments that described this phenomenon were carried out with uninfected cells. The antiproliferative effect of IFN-y on cultured cells and its toxic effects in vivo may also be a consequence of tryptophan degradation and, thus, may be reversible by an increased supply of this amino acid.
Note Added in Proof. When this manuscript was prepared, I was unaware of the important observation that high doses of IFN-/3 (104 units/ml) induced indoleamine 2,3-dioxygenase [indoleamine:oxygen 2,3-oxidoreductase (decyclizing)] in mouse lung slices (22) . I am indebted to Dr. Carl Nathan for bringing this work to my attention. The enzyme induced by physiological doses of INF-y described in this report is probably also indoleamine dioxygenase.
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